Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmelo Rizzari

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
Cancer Medicine|September 10, 2024
Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort studyNicolás Tentoni, Miriam Hwang, Gabriela Villanueva, et al.
Haematologica|September 13, 2005
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 studyMaurizio Aricò, Valentino Conter, Maria Grazia Valsecchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemiaAndrea Pession, Maria Grazia Valsecchi, Giuseppe Masera, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulationsAndrea Ballerini, Federico Moro, Ilaria Fuso Nerini, et al.
Pediatric Blood & Cancer|March 7, 2022
NUP214-ABL1 fusion in childhood T-ALLGiulia Veltri, Max Sandei, Daniela Silvestri, et al.
Pediatric Blood & Cancer|May 6, 2016
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute LeukemiaMaddalena Paganin, Barbara Buldini, Giuseppe Germano, et al.
Cancers|May 28, 2022
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)Luca Lo Nigro, Nellina Andriano, Barbara Buldini, et al.
Blood Advances|October 6, 2021
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatmentMartina Chiu, Giuseppe Taurino, Erica Dander, et al.
Therapeutic Drug Monitoring|December 7, 2017
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 TrialClaudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, et al.
British Journal of Haematology|May 13, 2024
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic targetGiuseppe Taurino, Erica Dander, Martina Chiu, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
Cancer Medicine|September 10, 2024
Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort studyNicolás Tentoni, Miriam Hwang, Gabriela Villanueva, et al.
Haematologica|September 13, 2005
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 studyMaurizio Aricò, Valentino Conter, Maria Grazia Valsecchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemiaAndrea Pession, Maria Grazia Valsecchi, Giuseppe Masera, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulationsAndrea Ballerini, Federico Moro, Ilaria Fuso Nerini, et al.
Pediatric Blood & Cancer|March 7, 2022
NUP214-ABL1 fusion in childhood T-ALLGiulia Veltri, Max Sandei, Daniela Silvestri, et al.
Pediatric Blood & Cancer|May 6, 2016
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute LeukemiaMaddalena Paganin, Barbara Buldini, Giuseppe Germano, et al.
Cancers|May 28, 2022
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)Luca Lo Nigro, Nellina Andriano, Barbara Buldini, et al.
Blood Advances|October 6, 2021
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatmentMartina Chiu, Giuseppe Taurino, Erica Dander, et al.
Therapeutic Drug Monitoring|December 7, 2017
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 TrialClaudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, et al.
British Journal of Haematology|May 13, 2024
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic targetGiuseppe Taurino, Erica Dander, Martina Chiu, et al.
Pageof 15